Raw signal, scraped and timestamped.

Service NOW, now is its time. With earnings coming up, buying under 100$ is litterally almost at the very bottom, its all up from here.

I built forensic engine that tracked 90+ crypto influencers' price calls and tweets. I just open-sourced the entire grading algorithm.

MSFT $40,000 YOLO

Actual cost basis for the shares is \~$412 due to a few sold calls that expired worthless. Hoping for a run up back to $420 or so, in addition to an IV spike going in to the July earnings. Wish …

Trump’s quantum announcement is out. What’s your top quantum play right now? $RGTI, $QBTS, $IONQ, or $IBM?

Why I’m staying away from BZAI: China exposure + specific short-seller red flags

Not financial advice. I’m not making any accusation of fraud, and I’m not saying the short reports are proven. I’m just explaining why BZAI is outside my risk tolerance. BZAI has an interesting edge AI / AI chip story, but …

Options Strategies for ML Model

Hello All, I'm not new to options trading (have a few years experience), but more wanted to ask for advice on what the best strategy would be given the results of my model. I felt this warranted its own post …

MU price pinning around 1060/1050 level pre-earnings

Massive put OI at that level for Friday expiry, looks like this price level is shaping up to be the launch pad for the implied move tomorrow

Will robotaxis kill Uber?

Some of us think that self-driving cars will end Uber. which makes sense, cause we won't need the middleman anymore. So the stock will take a hit. But Uber just announced a robotaxi deal in Munich. And the detail few …

A quick question for those that believe the future global currency will be only BitCoin

If the only global currency is BitCoin and all other currencies no longer exist .... How much will a two story house cost in BTC? You are not escaping the fiat system. You are just rebuilding it with a digital …

$CUE DD: Multi-Catalyst Immunology Platform With Multiple Shots on Goal 🧬

Been digging into **Cue Biopharma ($CUE)** and it looks like an interesting small-cap biotech setting up for several potential catalysts over the next 6-12 months. **What they do:** Cue is developing precision immunotherapies designed to selectively activate or regulate immune …